Dual bronchodilator combinations are being considered as the new gold standard over long-acting muscarinic antagonist (LAMA) Spiriva in the treatment of more severe COPD. 

IL-5 inhibitors have disappointed in the broader population of more severe COPD patients. However, ongoing studies are evaluating AstraZeneca’s Fasenra and GlaxoSmithKline's Nucala in individuals with high eosinophils. Topline results from Fasenra’s RESOLUTE and Nucala’s MATINEE trials are expected in the coming years, as are Phase III results from Sanofi and Regeneron’s dual IL-4 and IL-13 inhibitor Dupixent. 

This Datamonitor Healthcare report contains a Disease Analysis module.